Asian head and neck cancer patients live longer with immunotherapy than mixed race group

(European Society for Medical Oncology) Asian head and neck cancer patients live longer with the immunotherapy pembrolizumab than the overall population, according to a sub-analysis of the KEYNOTE-012 trial presented at the ESMO ASIA 2016 Congress in Singapore.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2hy8YFr